What to Expect from Antibody Assays of SARS-CoV-2?
作者信息
Yi Xin, Cao Jing
机构信息
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX.
Department of Pathology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
出版信息
J Appl Lab Med. 2020 Sep 1;5(5):1126-1130. doi: 10.1093/jalm/jfaa100.
Abstract
摘要
相似文献
1
What to Expect from Antibody Assays of SARS-CoV-2?
J Appl Lab Med. 2020 Sep 1;5(5):1126-1130. doi: 10.1093/jalm/jfaa100.
2
Serum IgA, IgM, and IgG responses in COVID-19.
Cell Mol Immunol. 2020 Jul;17(7):773-775. doi: 10.1038/s41423-020-0474-z. Epub 2020 May 28.
3
Serologic testing of coronaviruses from MERS-CoV to SARS-CoV-2: Learning from the past and anticipating the future.
Travel Med Infect Dis. 2020 Sep-Oct;37:101785. doi: 10.1016/j.tmaid.2020.101785. Epub 2020 Jun 10.
4
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
JCI Insight. 2020 Sep 17;5(18):142386. doi: 10.1172/jci.insight.142386.
5
Evaluation of an Electrochemiluminescent SARS-CoV-2 Antibody Assay.
J Appl Lab Med. 2020 Nov 1;5(6):1313-1323. doi: 10.1093/jalm/jfaa134.
6
Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA for Detecting SARS-CoV-2 IgG.
J Appl Lab Med. 2020 Nov 1;5(6):1416-1420. doi: 10.1093/jalm/jfaa133.
7
Selecting a SARS-CoV-2/COVID Molecular Testing Method for Your Laboratory.
J Appl Lab Med. 2020 Jul 1;5(4):837-840. doi: 10.1093/jalm/jfaa076.
8
A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.
J Appl Lab Med. 2020 Nov 1;5(6):1401-1405. doi: 10.1093/jalm/jfaa137.
9
Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.
Isr Med Assoc J. 2020 Apr;22(4):203-210.
10
Diagnostic testing for SARS-CoV-2.
CMAJ. 2020 Jun 29;192(26):E713. doi: 10.1503/cmaj.200858. Epub 2020 Jun 3.
引用本文的文献
1
COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort.
Sci Adv. 2024 Jun 14;10(24):eadi1379. doi: 10.1126/sciadv.adi1379. Epub 2024 Jun 12.
本文引用的文献
1
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
2
Developing antibody tests for SARS-CoV-2.
Lancet. 2020 Apr 4;395(10230):1101-1102. doi: 10.1016/S0140-6736(20)30788-1.
3
Virological assessment of hospitalized patients with COVID-2019.
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
4
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23.
5
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).
Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.
Zotero 插件